DaVita stock enters October 23 report after Q2 earnings beat

Published on 10/05/2026 at 22:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

DaVita stock posted adjusted Q2 EPS of USD 4.02 versus USD 3.88 consensus, with revenue up 5.2 percent to USD 3.55 billion. The October 5 NYSE quote was USD 178.72.

Schwarzweiß-Reportagefoto eines Dialysepatienten mit Pflegekraft in Klinikumgebung — Dokumentarische Schwarzweiß-Aufnahme eines Dialysepatienten der DaVita Inc. mit Pflegekraft beim Behandeln, ISIN US23918K1088, Illustration mit AI erstellt.

DaVita Inc. (ISIN US23918K1088) was last at USD 178.72 on the NYSE on October 5, 2026, up 0.02 percent from the prior session. The kidney-care provider heads toward its next earnings report on October 23, 2026, giving investors a dated checkpoint after a quarterly earnings beat.

Q2 earnings beat expectations

DaVita's second-quarter 2026 adjusted EPS reached USD 4.02 against USD 3.88 consensus, while revenue rose 5.2 percent year over year to USD 3.55 billion, according to MarketBeat on September 18, 2026. The EPS result exceeded consensus by USD 0.14, while the revenue comparison showed a 5.2 percent year-over-year increase.

The same report said DaVita posted USD 2.95 EPS in the year-earlier quarter, placing the latest adjusted result USD 1.07 higher. Fiscal 2026 adjusted EPS guidance stood at USD 14.10 to USD 15.20.

Guidance meets operating pressure

DaVita reaffirmed a full-year adjusted operating income midpoint of USD 2.2 billion and adjusted EPS midpoint of USD 14.65 in its Q2 call, according to Fortune on August 4, 2026. The company also reported USD 579 million of adjusted operating income, USD 256 million of free cash flow and treatment growth of 56 basis points versus Q2 2025.

The operating detail is mixed. Revenue per treatment was 3.6 percent higher in the first half of 2026 than in the first half of 2025, while management identified a USD 40 million full-year headwind from commercial mix changes, according to Fortune.

Analyst target stays above quote

MarketBeat reported on September 18, 2026, that seven research firms carried a Moderate Buy consensus, with four Buy ratings and three Holds. The average 12-month price target was USD 233.43, which lies 30.6 percent above the October 5 price of USD 178.72.

That spread places the upcoming October 23 report at the center of the valuation debate: the market is weighing double-digit adjusted EPS guidance against reimbursement and commercial-mix pressures. The next quarter's revenue trend and treatment volume will show whether the Q2 operating trajectory is carrying into the second half.

Stock stays inside yearly range

DaVita was last at USD 178.72 on the NYSE at 4:00 p.m. ET on October 5, 2026, with a market capitalization of USD 11.5 billion and a 52-week range of USD 101.00 to USD 247.49.